Daclizumab
drugOn this page
Also known as Daclizumab betaZenapaxZinbryta
Summary
Daclizumab (CHEMBL1201605) is an approved antibody (ATC L04AC01) targeting IL2RA; indicated across 29 conditions including immune system disorder and relapsing-remitting multiple sclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC01
- Targets: 1 (IL2RA)
- Indications: 29 conditions
- Clinical trials: 57
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201605 |
| Name | Daclizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC01 |
Also known as: Daclizumab, Daclizumab beta, Zenapax, Zinbryta, DACLIZUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IL2RA | Interleukin-2 receptor subunit α | Binding | 8 | 0.3% | P01589 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IL2RA.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| RAF/MAP kinase cascade | 1 | IL2RA |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | 1 | IL2RA |
| Interleukin-2 signaling | 1 | IL2RA |
| Interleukin receptor SHC signaling | 1 | IL2RA |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| inflammatory response to antigenic stimulus | 1 |
| regulation of T cell tolerance induction | 1 |
| apoptotic process | 1 |
| activation-induced cell death of T cells | 1 |
| inflammatory response | 1 |
| immune response | 1 |
| cell surface receptor signaling pathway | 1 |
| Notch signaling pathway | 1 |
| interleukin-2-mediated signaling pathway | 1 |
| positive regulation of activated T cell proliferation | 1 |
| negative regulation of T cell proliferation | 1 |
| positive regulation of T cell differentiation | 1 |
| regulation of T cell homeostatic proliferation | 1 |
| negative regulation of inflammatory response | 1 |
| activated T cell proliferation | 1 |
Indications & clinical
Indications
29 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| relapsing-remitting multiple sclerosis | 4 | MONDO:0005314 | EFO:0003929 |
| multiple sclerosis | 4 | MONDO:0005301 | MONDO:0005301 |
| graft versus host disease | 3 | MONDO:0013730 | MONDO:0013730 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| chronic kidney disease | 3 | MONDO:0005300 | MONDO:0024327 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| diabetes mellitus | 2 | MONDO:0005015 | EFO:0000400 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| ulcerative colitis | 2 | MONDO:0005101 | EFO:0000729 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| granulomatosis with polyangiitis | 2 | MONDO:0012105 | EFO:0005297 |
| uveitis | 2 | MONDO:0020283 | EFO:1001231 |
| thrombocytopenia | 2 | MONDO:0002049 | HP:0001873 |
| aplastic anemia | 2 | MONDO:0015909 | HP:0001915 |
| asthma | 2 | MONDO:0004979 | MONDO:0004979 |
| plasma cell neoplasm | 2 | MONDO:0004959 | EFO:0000200 |
| age-related macular degeneration | 2 | MONDO:0005150 | EFO:0001365 |
| Diamond-Blackfan anemia | 2 | MONDO:0015253 | MONDO:0015253 |
| choroidal neovascularization | 2 | MONDO:0810000 | MONDO:0810000 |
| psoriasis | 1 | MONDO:0005083 | EFO:0000676 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| melanoma | 1 | MONDO:0005105 | EFO:0000756 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| DiGeorge syndrome | 1 | MONDO:0008564 | MONDO:0018923 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 57.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 22 |
| PHASE4 | 11 |
| PHASE3 | 8 |
| PHASE1/PHASE2 | 8 |
| PHASE1 | 4 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00048165 | PHASE4 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation |
| NCT00231764 | PHASE4 | COMPLETED | MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients |
| NCT00246129 | PHASE4 | COMPLETED | CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation |
| NCT00363116 | PHASE4 | COMPLETED | A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients |
| NCT00493194 | PHASE4 | UNKNOWN | Fibrosis in Renal Allografts |
| NCT00574470 | PHASE4 | COMPLETED | Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD |
| NCT00681343 | PHASE4 | COMPLETED | Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation |
| NCT00685061 | PHASE4 | COMPLETED | Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation |
| NCT01172418 | PHASE4 | COMPLETED | Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols |
| NCT02554955 | PHASE4 | COMPLETED | A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants |
| NCT02576145 | PHASE4 | COMPLETED | A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax) |
| NCT00048152 | PHASE3 | COMPLETED | A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients |
| NCT00053976 | PHASE3 | COMPLETED | Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease |
| NCT00181142 | PHASE2/PHASE3 | COMPLETED | The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation |
| NCT00195273 | PHASE3 | COMPLETED | Study Evaluating Sirolimus in Kidney Transplant Recipients |
| NCT00275509 | PHASE3 | COMPLETED | Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch |
| NCT00296348 | PHASE3 | COMPLETED | Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation |
| NCT00682292 | PHASE3 | COMPLETED | Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk |
| NCT02686619 | PHASE3 | COMPLETED | Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients |
| NCT02881567 | PHASE3 | TERMINATED | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab |
| NCT00001865 | PHASE2 | COMPLETED | HAT in Eye Complications of Behcet’s Disease |
| NCT00001934 | PHASE2 | COMPLETED | Zenapax to Treat Multiple Sclerosis |
| NCT00001941 | PHASE1/PHASE2 | COMPLETED | Anti-Tac for Treatment of Leukemia |
| NCT00001962 | PHASE2 | TERMINATED | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure |
| NCT00002681 | PHASE1/PHASE2 | COMPLETED | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma |
| NCT00006350 | PHASE2 | COMPLETED | Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer |
| NCT00014911 | PHASE2 | COMPLETED | Islet Transplantation for Type 1 Diabetes |
| NCT00028288 | PHASE2 | COMPLETED | Study of Daclizumab in Patients With Chronic, Persistent Asthma |
| NCT00040248 | PHASE2 | COMPLETED | Daclizumab to Treat Wegener’s Granulomatosis |
| NCT00043667 | PHASE2 | COMPLETED | Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis |
| NCT00049725 | PHASE2 | COMPLETED | Daclizumab to Treat Chronic Immune Thrombocytopenia |
| NCT00050648 | PHASE1/PHASE2 | COMPLETED | To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris |
| NCT00050661 | PHASE1/PHASE2 | COMPLETED | To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris |
| NCT00064714 | PHASE2 | COMPLETED | Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes |
| NCT00070759 | PHASE2 | COMPLETED | Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis |
| NCT00071838 | PHASE2 | COMPLETED | Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis |
| NCT00072969 | PHASE2 | COMPLETED | A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) |
| NCT00073047 | PHASE2 | COMPLETED | Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis |
| NCT00100178 | PHASE2 | COMPLETED | New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial |
| NCT00109161 | PHASE2 | COMPLETED | Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).